First compound identified as truly selective GH secretagogue. Mimics natural GH pulsatility. Does not affect cortisol, prolactin, or ACTH unlike GHRP-2/6.
GH optimization, post-surgical recovery, body composition, anti-aging. Frequently paired with CJC-1295. Off-label compounding.
Active malignancy. Diabetes/insulin resistance. Pregnancy.
Phase I/II confirming selective GH pulse stimulation. GI Phase II failed primary endpoint. Extensive off-label compounding use in absence of body composition RCT evidence.
- 1.Raun K et al., Eur J Endocrinol 1998 — first compound to selectively release GH without affecting ACTH, cortisol, FSH, LH, prolactin, or TSH. Preclinical/Phase I
No published RCTs demonstrating body composition, fat loss, or performance outcomes. CJC-1295/Ipamorelin stack has ZERO RCT evidence. FDA flagged compounding safety concerns. WADA prohibited.
Remains most commonly prescribed GH secretagogue in US clinical practice. Combination protocols with GHRH analogs.